Medical Marijuana: Where’s the Data?

As more states legalize therapeutic cannabis, some caution against overprescribing the drug, the benefits of which have not been rigorously tested in clinical trials.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, BOKSKEWith New York State poised to become the latest inductee into the legal medical marijuana club, The New York Times explored the science behind weed’s effect on the variety of ills it’s used to treat. The paper’s verdict? Research into the medical benefits of smoked cannabis is severely lacking, and few findings point to a definitive therapeutic effect in the growing list of ailments that some physicians prescribe marijuana to treat, according to new laws. “I just don’t think the evidence is there for these long lists,” Molly Cooke, a professor of medicine at the University of California, San Francisco, told the Times. “It’s been so hard to study marijuana. Policy makers are responding to thin data.”

As The Scientist reported in 2012, many researchers who would like to study the medical effects of smoked marijuana are stymied by nearly insurmountable obstacles to securing both research-grade supplies of the drug and funding for clinical studies. A scientist wishing to conduct a rigorous trial of smoked marijuana on a particular human disease must first register with the Drug Enforcement Administration and file an investigational new drug application with the Food and Drug Administration, among other formalities. Once all these hurdles are cleared, researchers must still win funding, which is in short supply even for less-controversial work. “It’s one thing to say we need to have more research, and it’s another thing to obstruct the research,” Steven Jenison, former medical director of New Mexico’s ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies